50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#56

Bremelanotide

Sexual HealthPT-141VyleesiBremelanotide Acetate

An FDA-approved melanocortin receptor agonist used for the treatment of hypoactive sexual desire disorder in premenopausal women, acting through central nervous system pathways rather than vascular mechanisms.

Share:

Overview

Bremelanotide is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors, particularly MC3R and MC4R, in the central nervous system. Originally derived from the tanning peptide Melanotan II, bremelanotide was developed by Palatin Technologies after researchers observed that Melanotan II produced sexual arousal as an unexpected side effect in clinical trials. Unlike phosphodiesterase-5 inhibitors (such as sildenafil) that work through peripheral vascular mechanisms, bremelanotide acts centrally in the brain to influence sexual desire and arousal pathways.

In March 2019, bremelanotide was approved by the FDA under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This made it only the second drug ever approved for this indication, following flibanserin (Addyi). The approval was based on the RECONNECT phase 3 clinical trial program, which demonstrated statistically significant improvements in sexual desire and reductions in distress related to low sexual desire compared to placebo.

The melanocortin system plays a well-established role in sexual function. MC4R activation in the hypothalamus and limbic system modulates sexual motivation and arousal through dopaminergic and oxytocinergic pathways. Bremelanotide's mechanism of action represents a fundamentally different approach to treating sexual dysfunction compared to agents that target peripheral blood flow or neurotransmitter reuptake.

Bremelanotide is administered as a subcutaneous autoinjector at least 45 minutes before anticipated sexual activity. Unlike daily-dosing medications, it is used on an as-needed basis. The drug has notable side effects including nausea (which affects approximately 40% of users) and transient increases in blood pressure, which have limited its widespread adoption.

Research Uses & Applications

  • FDA-approved treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women
  • Research into melanocortin-based treatment of sexual dysfunction in both sexes
  • Investigated for male erectile dysfunction in earlier clinical trials
  • Research tool for studying melanocortin receptor involvement in sexual behavior
  • Studied for potential effects on emotional and motivational circuits
  • Off-label use in men's health clinics for sexual dysfunction

Key Research Findings

  • The RECONNECT trials showed bremelanotide significantly increased sexual desire scores and decreased distress compared to placebo in women with HSDD (Obstetrics & Gynecology, 2019).
  • Earlier phase 2 studies in men with erectile dysfunction demonstrated pro-erectile effects independent of sexual stimulation, confirming central mechanism of action.
  • Neuroimaging research confirmed bremelanotide modulates brain activity in regions associated with sexual arousal and reward processing.
  • Studies showed bremelanotide increases dopamine release in the hypothalamus, consistent with melanocortin-dopamine interaction in sexual motivation.
  • Clinical data demonstrated the nausea side effect tends to diminish with repeated use, affecting approximately 40% at first use but decreasing over time.

Risks & Side Effects

  • Nausea is the most common side effect, affecting approximately 40% of patients, particularly with initial doses.
  • Transient increases in blood pressure; contraindicated in patients with uncontrolled hypertension or cardiovascular disease.
  • May cause hyperpigmentation, particularly in facial areas, with repeated use.
  • Injection site reactions including bruising, erythema, and pain.
  • Not recommended for use more than once within 24 hours or more than 8 times per month.

Administration

Administered as a subcutaneous injection using a single-dose autoinjector (1.75 mg per dose) at least 45 minutes before anticipated sexual activity. Used on an as-needed basis, not daily. Maximum recommended use is once per 24 hours and no more than 8 doses per month. Patients should be trained on autoinjector use.

Legal Status

FDA-approved prescription medication marketed as Vyleesi. Available by prescription only for premenopausal women with HSDD. The precursor compound PT-141 is widely available through research chemical suppliers and peptide clinics, existing in a regulatory gray area. Not a controlled substance.

Frequently Asked Questions

What is Bremelanotide?

An FDA-approved melanocortin receptor agonist used for the treatment of hypoactive sexual desire disorder in premenopausal women, acting through central nervous system pathways rather than vascular mechanisms.

What are the main uses of Bremelanotide?

The primary research applications of Bremelanotide include: FDA-approved treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women; Research into melanocortin-based treatment of sexual dysfunction in both sexes; Investigated for male erectile dysfunction in earlier clinical trials; Research tool for studying melanocortin receptor involvement in sexual behavior; Studied for potential effects on emotional and motivational circuits; Off-label use in men's health clinics for sexual dysfunction.

What are the risks and side effects of Bremelanotide?

Documented risks and side effects include: Nausea is the most common side effect, affecting approximately 40% of patients, particularly with initial doses.; Transient increases in blood pressure; contraindicated in patients with uncontrolled hypertension or cardiovascular disease.; May cause hyperpigmentation, particularly in facial areas, with repeated use.; Injection site reactions including bruising, erythema, and pain.; Not recommended for use more than once within 24 hours or more than 8 times per month.. Always consult a healthcare professional before considering any peptide.

Is Bremelanotide legal?

FDA-approved prescription medication marketed as Vyleesi. Available by prescription only for premenopausal women with HSDD. The precursor compound PT-141 is widely available through research chemical suppliers and peptide clinics, existing in a regulatory gray area. Not a controlled substance.

How is Bremelanotide administered?

Administered as a subcutaneous injection using a single-dose autoinjector (1.75 mg per dose) at least 45 minutes before anticipated sexual activity. Used on an as-needed basis, not daily. Maximum recommended use is once per 24 hours and no more than 8 doses per month. Patients should be trained on autoinjector use.

Related Peptides

#7

PT-141

Sexual Health

#55

Triptorelin

Reproductive Health

#57

Alarelin

Reproductive Health

#54

Gonadorelin

Reproductive Health

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #55 Triptorelin#57 Alarelin →